Free
Meeting Abstracts  |   August 2006
Modifying the Baricity of Local Anesthetics for Spinal Anesthesia by Temperature Adjustment: Model Calculations
Author Affiliations & Notes
  • Axel R. Heller, M.D., Ph.D., D.E.A.A.
    *
  • Katrin Zimmermann, cand. med.
  • Kristin Seele, cand. med.
  • Thomas Rössel, M.D.
  • Thea Koch, M.D., Ph.D.
    §
  • Rainer J. Litz, M.D.
  • * Associate Professor of Anesthesiology, † Medical Student, ‡ Resident in Anesthesiology, § Professor of Anesthesiology and Head of Department, ∥ Staff Anesthesiologist.
Article Information
Meeting Abstracts   |   August 2006
Modifying the Baricity of Local Anesthetics for Spinal Anesthesia by Temperature Adjustment: Model Calculations
Anesthesiology 8 2006, Vol.105, 346-353. doi:
Anesthesiology 8 2006, Vol.105, 346-353. doi:
THE ratio of the density of local anesthetics (LAs) and cerebrospinal fluid (CSF), which is known as LA baricity, is one key determinant of LA distribution within the subarachnoid space.1–3 Although LAs are hyperbaric outside the body, in particular when stored at room temperatures or below until use, density4 and viscosity5 decrease within minutes after administration into the subarachnoid space. As a result, at first LAs sink within the CSF according to posturing as long as the temperature difference to CSF is high with a substance-specific velocity. Adaptation of LAs to CSF temperature decelerates sedimentation velocity until LAs become hypobaric and therefore again ascend. Besides the effect of warming LAs on pK values, which drop and consequently cause nonionized LA fraction rises,6 the temperature-dependent change in baricity has been shown to cause faster onset of block as well as higher maximum sensory levels of block during spinal anesthesia (SPA).2,5,7 In line with these findings, hypobaric solutions prolonged analgesia for hip replacement surgery,8 and CSF density was significantly positively correlated with peak level of sensory block.9 On the contrary, controllability of SPA extent is traditionally assured by addition of dextrose, leading to hyperbaricity of the LA solution.10 However, late cranial extent of SPA after posture change has also been reported using hyperbaric11 as well as isobaric solutions.12 In this regard, the volume of administered LAs seems to be of minor relevance.2,13 
Measurements of CSF density have previously been performed by various authors,14–18 and the relationship to sex,17 pregnancy, or postmenopausal status18 is well established. A linear regression method to calculate the density of the admixture of glucose and opioids to LAs at a single temperature has been proposed by Hallworth et al.  19 with the same method used in the current study and by Hare and Ngan20 with pyknometer measurements of lower precision. Previously described densities or baricities of LAs in part lack reliability because methods used are no longer up-to-date or temperature dependency was not considered. This issue was already addressed in the early 1990s by Horlocker and Wedel,1 who stated, “Comparison of densities [of LA] measured at 25°C to the density of CSF at 37°C is scientifically unsound.” However, linear relations of density from temperature were insinuated in former reports, although merely two temperatures were measured,16,21 thus not allowing conclusions on the curve shape. Unlike other fluids, the density of water and aqueous solutions is a nonlinear function of temperature (T); rather, it is described being a monotonic polynomial equation.22,23 
We hypothesized that temperature and density of LA solutions have a nonlinear relation that may be described by a polynomial equation, and that conversion of this equation may provide the temperature at which individual LAs are isobaric. Therefore, we collected high-precision temperature-dependent data of CSF and LA density to fit them into mathematical models allowing reliable prediction of LA density in relation to temperature.
Materials and Methods
Our own CSF measurements were performed to obtain a reference quantity in the same methodologic setting for comparison with LA density data and to further calculate isobaric LA injection temperatures. After institutional review board approval (Ethikkommission der Medizinischen Fakultät Dresden, Germany, permission No. 168082004) and written informed consent, in seven male patients aged 45–60 yr undergoing SPA for transurethral resection of the prostate, the subarachnoid space was punctured at the L4–L5 interspace via  a median approach using a 25-gauge Sprotte cannula. Before LA application, 2 ml free-flowing CSF without aspirating was collected for instant analysis. The densities of CSF and all LAs commercially available in Germany (tables 1–3) as well as that of saline were determined by means of a digital vibrating tube densitometer (DMA 4500; Paar, Graz, Austria) with an accuracy of 10−5g/cm3at four temperature levels—5°, 20°, 30°, and 37°C24,25 —at least in triplicate. Measurements were routinely performed by the metabolism laboratory of the Department of Internal Medicine III, University Hospital Dresden, Germany. Reference measurements were provided by the Institute of Physical Chemistry, University of Rostock, Germany, showing a mean measurement-to-measurement variation of 3 × 10−6g/cm3.
Table 1. Density Formulae of Light Local Anesthetics 
Image not available
Table 1. Density Formulae of Light Local Anesthetics 
×
Table 2. Density Formulae for Intermediate-weight Local Anesthetics 
Image not available
Table 2. Density Formulae for Intermediate-weight Local Anesthetics 
×
Table 3. Density Formulae of Heavy Local Anesthetics 
Image not available
Table 3. Density Formulae of Heavy Local Anesthetics 
×
The oscillating U-tube densitometer is based on the principle of a U-tube, which has a resonant frequency that is inversely proportional to the square root of its mass. The volume of the tube is given; the density of the liquid sample filled into the U-tube is calculated from its resonant frequency. If calibrated previously with two media of known density, the densitometer calculates the true density. Calibration was performed before each single measurement with air and bi-distilled water. The temperature was controlled by an ultrathermostate with an accuracy of ±1 × 10−2°C.
Local anesthetics were obtained from AstraZeneca, Wedel, Germany (2, 5, 7.5, and 10 mg/ml ropivacaine [Naropin®]; 10 and 20 mg/ml prilocaine [Xylonest®]; 10 and 20 mg/ml mepivacaine [Scandicain®]; 2.5 and 5 mg/ml bupivacaine [Carbostesin®]); Abbott, Wiesbaden, Germany (2.5 and 5 mg/ml L-bupivacaine [Chirocain®]); Aventis-Pharma, Bad Soden, Germany (10 and 20 mg/ml articaine [Ultracain®]); Delta-Select, Pfullingen, Germany (2.5 and 5 mg/ml hyperbaric bupivacaine [Bucain®]); and Jenapharm, Jena, Germany (10 and 20 mg/ml lidocaine [Xylocitin®]).
Besides the original concentrations, LAs were diluted to clinically used concentrations with both sterile isotonic saline (sal) (Fresenius-Kabi, Bad Hombug, Germany) and distilled water (aq) (Ampuwa®; Fresenius-Kabi), respectively (microtiter pipette; Eppendorf, Hamburg, Germany). The measured concentrations were as follows: 2, 5, 7.5, and 10 mg/ml ropivacaine; 10, 15, and 20 mg/ml prilocaine; 10, 15, and 20 mg/ml mepivacaine; 2.5, 3.75, and 5 mg/ml “isobaric” bupivacaine; 2.5 and 5 mg/ml “hyperbaric” bupivacaine; 2.5, 3.75, and 5 mg/ml L-bupivacaine; 10, 15, and 20 mg/ml articaine; and 10, 15, and 20 mg/ml lidocaine.
Database aggregation and primary curve fit were performed with Excel 2003 SR1 software (Microsoft Deutschland, Unterschleißheim, Germany). Regression statistics and definite curve fit procedures were completed with SPSS software for MS Windows (Release 12.0.1), SPSS Inc., Chicago, IL.
In initial curve fit procedures, third-degree (f(x) = ax3+ bx2+ cx + d) and second-degree (f(x) = ax2+ bx + c) polynomial equations of excellent model validity (R  2= 1, P  < 0.0005) could be established for all measured LAs. Facilitating clinical application of the formula and enabling easy conversion of the models to obtain the factor temperature, more simple models in the general form of f(x) = ax2+ b were generated for each concentration of the LAs and still showed acceptable validity (tables 1–3).
Straightforward model selection may be conducted by using information criteria (e.g.  , Akaike’s criterion) that examine the complexity of the model together with goodness of its fit to the sample data, and to produce a measure that balances between the two, favoring simple models. Akaike’s criterion is computed as AIC = 2 k +n  ln (RSS/n), where k is the number of parameters, n is the number of observations and RSS is the residual sum of squares, which is directly proportional to R  2. Taking into account that all present models are based on the same number of observations and that they all solely contain the factor temperature, regardless of the number of (linear, quadratic, cubic, …) coefficients, the use of information criteria does not add much value to the simple consideration of R  2for the estimation of individual model quality in the current data set.
For further generalization of the models, substance-specific formulae (f(x,y) = ax2+ by + c) including temperature (°C) and  concentration (mg/ml) were established. The latter were, as a matter of generalization and the inherent increase of residuals, of slightly lower model power, but still acceptable. Regarding Akaike’s criterion, these more complex models, in addition using the factor concentration, are inferior to the models calculated for the fixed combinations of substance and concentration.
To limit the formula load for clinical issues to a minimum, we consequently calculated models for each of the three identified subgroups of LAs, differentiating between light LAs (lighter than saline), intermediate LAs (between saline and CSF), and heavy LAs (in the range of CSF), regardless of their concentration.
The final step was then to calculate substance- and concentration-specific ideal injection temperatures (TLAi) by combining formulae 1 and 2 (ρLA= LA density; TLA= LA temperature), insinuating that LA density ideally (ρLAi) equals CSF density (ρCSF) and CSF having body temperature, to receive equation 3.
Calculation of the ideal injection temperature by conversion of equation 3to equation 4is trivial.
Temperatures given in tables 1–3are calculated from mean CSF density. The upper and lower limits are calculated from mean CSF density ± 3 SDs, respectively. By introduction of population-specific CSF density data,17,18 ideal injection temperatures may likewise be calculated for these patients.
Results
The density (mean ± 1 SD) of CSF in the observed population (n = 7) was 1.000646 ± 0.000086 g/ml at 37°C; that of saline was 0.999748 ± 0.000001 g/ml. Temperature-dependent densities of local anesthetics can be found in figures 1–8. When defining the isobaric range according to Davis and King14 and Horlocker and Wedel,1 being mean CSF density ± 3 SDs, in all observed concentrations, bupivacaine, L-bupivacaine, ropivacaine, prilocaine, and lidocaine were found to be hypobaric at body temperature (figs. 1–3, 7, and 8). In contrast, 20 mg/ml articaine and 20 mg/ml mepivacaine remained slightly hyperbaric at body temperature (figs. 5 and 6). The only true isobaric LAs at 37°C were 10 and 15 mg/ml mepivacaine and 15 mg/ml articaine (figs. 5 and 6).
Fig. 1. Effects of temperature and concentration on the density of bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 1. Effects of temperature and concentration on the density of bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 1. Effects of temperature and concentration on the density of bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 2. Effects of temperature and concentration on the density of levo (L)–bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 2). L-bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 2. Effects of temperature and concentration on the density of levo (L)–bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 2). L-bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 2. Effects of temperature and concentration on the density of levo (L)–bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 2). L-bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 3. Effects of temperature and concentration on the density of ropivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Ropivacaine, 2, 5, 7.5, and 10 mg/ml as commercially available solutions, 5 mg/ml (aq) diluted from 10 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 3. Effects of temperature and concentration on the density of ropivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Ropivacaine, 2, 5, 7.5, and 10 mg/ml as commercially available solutions, 5 mg/ml (aq) diluted from 10 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 3. Effects of temperature and concentration on the density of ropivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Ropivacaine, 2, 5, 7.5, and 10 mg/ml as commercially available solutions, 5 mg/ml (aq) diluted from 10 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 4. Effects of temperature and concentration on the density of hyperbaric bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Note extended scale of y-axis  versus  all other figures. Hyperbaric (hyper) bupivacaine, 2.5 and 5 mg/ml as commercially available solutions.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 4. Effects of temperature and concentration on the density of hyperbaric bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Note extended scale of y-axis  versus  all other figures. Hyperbaric (hyper) bupivacaine, 2.5 and 5 mg/ml as commercially available solutions.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 4. Effects of temperature and concentration on the density of hyperbaric bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Note extended scale of y-axis  versus  all other figures. Hyperbaric (hyper) bupivacaine, 2.5 and 5 mg/ml as commercially available solutions.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 5. Effects of temperature and concentration on the density of articaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Articaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 5. Effects of temperature and concentration on the density of articaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Articaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 5. Effects of temperature and concentration on the density of articaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Articaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 6. Effects of temperature and concentration on the density of mepivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Mepivacaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 6. Effects of temperature and concentration on the density of mepivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Mepivacaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 6. Effects of temperature and concentration on the density of mepivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Mepivacaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 7. Effects of temperature and concentration on the density of lidocaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Lidocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 7. Effects of temperature and concentration on the density of lidocaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Lidocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 7. Effects of temperature and concentration on the density of lidocaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Lidocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 8. Effects of temperature and concentration on the density of prilocaine. Depicted are all measurements at least in triplicate per concentration at 5, 20, 30, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Prilocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 8. Effects of temperature and concentration on the density of prilocaine. Depicted are all measurements at least in triplicate per concentration at 5, 20, 30, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Prilocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 8. Effects of temperature and concentration on the density of prilocaine. Depicted are all measurements at least in triplicate per concentration at 5, 20, 30, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Prilocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Polynomial dependency of density from temperature was found in all LA preparations and could be described in simple quadratic mathematic models of satisfactory power (tables 1–3). Further, linear dependency of density from concentration was expectedly found (tables 1–3). In all cases, dilution with isotonic saline produced densities that fit into the characteristics of the commercially available preparations in the respective higher and lower concentrations. Dilution with distilled water, however, produced 0.001- to 0.003-g/ml lower densities at the same temperature and LA concentration, as compared with saline as diluent. Curve characteristics of 5 mg/ml bupivacaine and 5 mg/ml ropivacaine were identical (table 1).
Three groups of LAs with similar temperature-dependent density curve shape were identified: Bupivacaine, ropivacaine, prilocaine, and lidocaine were light LAs, being more hypobaric than saline at body temperature (table 1). L-bupivacaine had an intermediate position because its density lay between that of CSF and that of saline (table 2). Articaine and mepivacaine were heavy LAs and were fairly isobaric at body temperature (table 3).
Temperatures at which LAs had the same density as CSF at 37°C were calculated according to equation 4(see Materials and Methods) and can be found in tables 1–3.
Discussion
Baricity and the temperature of LAs are two closely related key factors affecting the cranial extent of SPA.1–3 Temperature adjustment of LAs for SPA to body temperature has been performed by our group and others, showing improvement of predictability of the SPA.2,5,7 Data from Higuchi et al.  9 showing significant positive correlation between CSF density and peak level of sensory block indirectly support the clinical impact of LA density adjustment to CSF density.
A number of authors previously described densities of both LAs1,10,16,19–21 and CSF.9,14–18 However, a thorough high-precision description and modeling of the density–temperature relation of LAs is lacking. This is the first study to describe reliable polynomial models to predict LA densities over the clinical relevant range of temperature. Previously described densities or baricities of LAs in part lack reliability because methods are not contemporary1,9,14,26 or temperature dependency was not considered.13 In the current study, high-precision data were collected at least in triplicate at four defined temperature levels of each concentration of the respective LAs. Because previous studies gave LA densities without reporting temperature or merely at one or two temperature levels,16,21 conclusions on the curve shape could not been drawn, and the assumption of linear relation of temperature and density was speculative.
Unlike most fluids, density of water and likewise of aqueous solutions is a nonlinear function of temperature; rather, it is described as being a monotonic polynomial equation up to the fifth degree.22,23 This notion is a fundamental issue in oceanographic predictive models of ocean currents and meteorology. The polynomial nature of the dependence of LA density from temperature has not yet been addressed. If LA baricities defined as ρLACSFare compared, the problem of nonlinearity does not exist when corresponding LA and CSF densities are obtained at the same temperature level. By dividing LA density by CSF density, the commonly underlying polynomial factor temperature is then eliminated (divide the right side of equation 1by the accordingly formulated ρCSF). However, because of complex protein interactions with density, viscosity, and pH value, it is not advisable to measure density of CSF outside a narrow range from body temperature. Therefore, the polynomial problem remains when comparing stationary CSF density (37°C) with temperature-variable LA density. Hence, it seemed most stringent to observe CSF density solely at body temperature as we usually find it in the clinical setting and face the problem of nonlinearity in the current work (figures 1–8).
In this regard, the cooling effect of the injected LA on CSF, when administered below body temperature, must be addressed.26,27 As a consequence of cooling CSF, the baricity of any given LA would slightly decrease until the baseline of CSF temperature is regained. This topic is rather difficult to predict and may not have the impact one would expect at first glance. First, CSF volume of patients is highly variable and individually merely not predictable.9 Second, the subarachnoid space is not only a CSF-filled tube27; rather, solid structures (cauda equina, nerve roots, blood-perfused arachnoidea) with a far higher specific temperature capacity keep CSF temperature fairly stable. Despite this stable in vivo  temperature condition of CSF, injection of LAs at room temperature showed slower onset of SPA and a lower maximum sensory level of block as compared with LAs injected at body temperature.5,7 
Polynomial equations of second or third degree for the investigated LA solutions were calculated by the authors (equations not shown). For clinical use, the accuracy of even more simple equations in the form ρ(T) = aT2+ b is acceptable (R  2> 0.998, P  < 0.01; tables 1–3). Moreover, simple equations increase clinical utility and facilitate comparisons between the curve shapes of different LAs and are in accordance with straightforward model selection information criteria (e.g.  , Akaike’s criterion) as addressed in the Materials and Methods section. In this regard, the observed identical curve shapes of bupivacaine and ropivacaine in the 5-mg/ml concentration (figs. 1 and 3) may allow conclusions on comparable distribution of both LAs within the CSF with respect to the factor density.
In the current study, CSF density was obtained from male patients who were reported to have higher CSF density as compared with females (table 4). Therefore, mean isobaric temperature ranges will vary when using different CSF data. Keeping in mind the steep slope of the temperature–density curve around body temperature, slight subpopulation-specific variations of CSF density will not produce large variations in the isobaric temperature range. Computation of all given formulae (table 1–3) with the mean CSF data for the female patients reported by Schiffer et al.  17 (table 4) produced 0.2°–0.6°C higher isobaric LA temperatures.
Table 4. Density of Cerebrospinal Fluid in Respective Populations 
Image not available
Table 4. Density of Cerebrospinal Fluid in Respective Populations 
×
The presented models derived from high-quality measurements of the variety of LAs within one standard methodologic data set may serve as reference formulae that allow comparison of all substances in this regard. Further, conversion of the formula allows for calculation of the substance specific isobaric temperature, even in other populations of known CSF density.9,15–18 Direct clinical advice cannot be derived from the current laboratory investigation. In synopsis with in vivo  data,5,7 administration of LAs at their isobaric temperature may help to control one of the key factors of LA distribution in the CSF. Whether this concept in fact improves patient safety in terms of hemodynamic stability or even allows dose reductions of LA must be confirmed in further clinical studies.
The authors thank Sigrid Nitzsche (Department of Internal Medicine III, University Hospital Dresden, Dresden, Germany) for technical support; Prof. Edmund Koch, Ph.D. (Head of the Department of Clinical Sensoring and Monitoring, Medical Faculty Dresden, Germany), for briefing in curve fit analysis; and Dipl. Math. Dr. Johannes Novotný (Bavarian State Ministry of Culture and Education, Munich, Germany) for mathematic review.
References
Horlocker TT, Wedel DJ: Density, specific gravity, and baricity of spinal anesthetic solutions at body temperature. Anesth Analg 1993; 76:1015–8Horlocker, TT Wedel, DJ
Stienstra R, Gielen M, Kroon JW, Van PF: The influence of temperature and speed of injection on the distribution of a solution containing bupivacaine and methylene blue in a spinal canal model. Reg Anesth 1990; 15:6–11Stienstra, R Gielen, M Kroon, JW Van, PF
Greene NM: Distribution of local anesthetic solutions within the subarachnoid space. Anesth Analg 1985; 64:715–30Greene, NM
Bucx MJ, Kroon JW, Stienstra R: Effect of speed of injection on the maximum sensory level for spinal anesthesia using plain bupivacaine 0.5% at room temperature. Reg Anesth 1993; 18:103–5Bucx, MJ Kroon, JW Stienstra, R
Arai YC, Ueda W, Takimoto E, Manabe M: The influence of hyperbaric bupivacaine temperature on the spread of spinal anesthesia. Anesth Analg 2006; 102:272–5Arai, YC Ueda, W Takimoto, E Manabe, M
Kamaya H, Hayes JJ Jr, Ueda I: Dissociation constants of local anesthetics and their temperature dependence. Anesth Analg 1983; 62:1025–30Kamaya, H Hayes, JJ Ueda, I
Litz RJ, Reytan N, Vicent O, Wiessner D, Heller AR, Koch T: The influence of the temperature of bupivacaine 0.5% used for lumbosacral spinal anaesthesia (Taylor’s approach) on onset and extent of block (abstract). Eur J Anaesthesiol 2005; 22:97.Litz, RJ Reytan, N Vicent, O Wiessner, D Heller, AR Koch, T
Faust A, Fournier R, Van GE, Weber A, Hoffmeyer P, Gamulin Z: Isobaric versus  hypobaric spinal bupivacaine for total hip arthroplasty in the lateral position. Anesth Analg 2003; 97:589–94Faust, A Fournier, R Van, GE Weber, A Hoffmeyer, P Gamulin, Z
Higuchi H, Hirata J, Adachi Y, Kazama T: Influence of lumbosacral cerebrospinal fluid density, velocity, and volume on extent and duration of plain bupivacaine spinal anesthesia. Anesthesiology 2004; 100:106–14Higuchi, H Hirata, J Adachi, Y Kazama, T
McLeod GA: Density of spinal anaesthetic solutions of bupivacaine, levobupivacaine, and ropivacaine with and without dextrose. Br J Anaesth 2004; 92:547–51McLeod, GA
Povey HM, Jacobsen J, Westergaard-Nielsen J: Subarachnoid analgesia with hyperbaric 0.5% bupivacaine: Effect of a 60-min period of sitting. Acta Anaesthesiol Scand 1989; 33:295–7Povey, HM Jacobsen, J Westergaard-Nielsen, J
Vicent O, Litz RJ, Hubler M, Koch T: Secondary cranial extension after spinal anesthesia with isobaric 0.5% bupivacaine following postural change [in German]. Anaesthesist 2003; 52:1035–8Vicent, O Litz, RJ Hubler, M Koch, T
Malinovsky JM, Renaud G, Le CP, Charles F, Lepage JY, Malinge M, Cozian A, Bouchot O, Pinaud M: Intrathecal bupivacaine in humans: Influence of volume and baricity of solutions. Anesthesiology 1999; 91:1260–6Malinovsky, JM Renaud, G Le, CP Charles, F Lepage, JY Malinge, M Cozian, A Bouchot, O Pinaud, M
Davis H, King WR: Densities of cerebrospinal fluid of human beings. Anesthesiology 1954; 15:666–72Davis, H King, WR
Becker J, Theiss D, Lanz E, Erdmann K: Density of cerebrospinal fluid and local anesthetics [author’s translation]. Anaesthesist 1979; 28:81–3Becker, J Theiss, D Lanz, E Erdmann, K
Levin E, Muravchick S, Gold MI: Density of normal human cerebrospinal fluid and tetracaine solutions. Anesth Analg 1981; 60:814–7Levin, E Muravchick, S Gold, MI
Schiffer E, Van GE, Gamulin Z: Influence of sex on cerebrospinal fluid density in adults. Br J Anaesth 1999; 83:943–4Schiffer, E Van, GE Gamulin, Z
Richardson MG, Wissler RN: Density of lumbar cerebrospinal fluid in pregnant and nonpregnant humans. Anesthesiology 1996; 85:326–30Richardson, MG Wissler, RN
Hallworth SP, Fernando R, Stocks GM: Predicting the density of bupivacaine and bupivacaine-opioid combinations. Anesth Analg 2002; 94:1621–4Hallworth, SP Fernando, R Stocks, GM
Hare GM, Ngan JC: Density determination of local anaesthetic opioid mixtures for spinal anaesthesia. Can J Anaesth 1998; 45:341–6Hare, GM Ngan, JC
Nicol ME, Holdcroft A: Density of intrathecal agents. Br J Anaesth 1992; 68:60–3Nicol, ME Holdcroft, A
Cho CH, Singh S, Robinson GW: Understanding all of water’s anomalies with a nonlocal potential. J Chem Phys 1997; 107:7979–88Cho, CH Singh, S Robinson, GW
Tanaka H: Simple physical explanation of the unusual thermodynamic behavior of liquid water. Phys Rev Lett 1998; 80:5750–3Tanaka, H
Hinghofer-Szalkay H: Volume and density changes of biological fluids with temperature. J Appl Physiol 1985; 59:1686–9Hinghofer-Szalkay, H
Hinghofer-Szalkay H: Method of high-precision microsample blood and plasma mass densitometry. J Appl Physiol 1986; 60:1082–8Hinghofer-Szalkay, H
Davis H, King WR: Densities of common spinal anesthetic solutions at body temperature. Anesthesiology 1952; 13:184–8Davis, H King, WR
Ernst EA: In vitro  changes of osmolality and density of spinal anesthetic solutions. Anesthesiology 1968; 29:104–9Ernst, EA
Fig. 1. Effects of temperature and concentration on the density of bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 1. Effects of temperature and concentration on the density of bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 1. Effects of temperature and concentration on the density of bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 2. Effects of temperature and concentration on the density of levo (L)–bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 2). L-bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 2. Effects of temperature and concentration on the density of levo (L)–bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 2). L-bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 2. Effects of temperature and concentration on the density of levo (L)–bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 2). L-bupivacaine, 5 and 2.5 mg/ml as commercially available solutions, 3.75 mg/ml (NaCl) diluted from 5 mg/ml with isotonic saline, 3.75 mg/ml (aq) diluted from 5 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 3. Effects of temperature and concentration on the density of ropivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Ropivacaine, 2, 5, 7.5, and 10 mg/ml as commercially available solutions, 5 mg/ml (aq) diluted from 10 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 3. Effects of temperature and concentration on the density of ropivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Ropivacaine, 2, 5, 7.5, and 10 mg/ml as commercially available solutions, 5 mg/ml (aq) diluted from 10 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 3. Effects of temperature and concentration on the density of ropivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Ropivacaine, 2, 5, 7.5, and 10 mg/ml as commercially available solutions, 5 mg/ml (aq) diluted from 10 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 4. Effects of temperature and concentration on the density of hyperbaric bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Note extended scale of y-axis  versus  all other figures. Hyperbaric (hyper) bupivacaine, 2.5 and 5 mg/ml as commercially available solutions.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 4. Effects of temperature and concentration on the density of hyperbaric bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Note extended scale of y-axis  versus  all other figures. Hyperbaric (hyper) bupivacaine, 2.5 and 5 mg/ml as commercially available solutions.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 4. Effects of temperature and concentration on the density of hyperbaric bupivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Note extended scale of y-axis  versus  all other figures. Hyperbaric (hyper) bupivacaine, 2.5 and 5 mg/ml as commercially available solutions.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 5. Effects of temperature and concentration on the density of articaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Articaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 5. Effects of temperature and concentration on the density of articaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Articaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 5. Effects of temperature and concentration on the density of articaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Articaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 6. Effects of temperature and concentration on the density of mepivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Mepivacaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 6. Effects of temperature and concentration on the density of mepivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Mepivacaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 6. Effects of temperature and concentration on the density of mepivacaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 3). Mepivacaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 7. Effects of temperature and concentration on the density of lidocaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Lidocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 7. Effects of temperature and concentration on the density of lidocaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Lidocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 7. Effects of temperature and concentration on the density of lidocaine. Depicted are all measurements at least in triplicate per concentration at 5°, 20°, 30°, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Lidocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Fig. 8. Effects of temperature and concentration on the density of prilocaine. Depicted are all measurements at least in triplicate per concentration at 5, 20, 30, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Prilocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 8. Effects of temperature and concentration on the density of prilocaine. Depicted are all measurements at least in triplicate per concentration at 5, 20, 30, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Prilocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
Fig. 8. Effects of temperature and concentration on the density of prilocaine. Depicted are all measurements at least in triplicate per concentration at 5, 20, 30, and 37°C and polynomial curve fits (  P  and  R  2given in  table 1). Prilocaine, 10 and 20 mg/ml as commercially available solutions, 15 mg/ml (NaCl) diluted from 20 mg/ml with isotonic saline, 15 mg/ml (aq) diluted from 20 mg/ml with distilled water.  Horizontal line  = cerebrospinal fluid (CSF) (n = 7) at 37°C;  gray bar  = 3-SD range. 
×
Table 1. Density Formulae of Light Local Anesthetics 
Image not available
Table 1. Density Formulae of Light Local Anesthetics 
×
Table 2. Density Formulae for Intermediate-weight Local Anesthetics 
Image not available
Table 2. Density Formulae for Intermediate-weight Local Anesthetics 
×
Table 3. Density Formulae of Heavy Local Anesthetics 
Image not available
Table 3. Density Formulae of Heavy Local Anesthetics 
×
Table 4. Density of Cerebrospinal Fluid in Respective Populations 
Image not available
Table 4. Density of Cerebrospinal Fluid in Respective Populations 
×